Sanofi Consumer Healthcare India Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Strong post-demerger quarter, recall recovery underway: Revenue from operations grew 21% in 2025, driven by organizational rebuilding, brand reinvestment, and the relaunch of all recalled products.
• Brand equity proved resilient: Combiflam remained a top-five brand despite zero HCP engagement for 15 years, and HCPs welcomed the return of recalled products because alternatives underperformed.
• Investment phase is deliberate and ongoing: A&P spend has moved from very low single digits to mid-teens, with first-time investments in retail pharmacy visibility, direct consumer communication, and AI-enabled creative teams.
• Growth is the unambiguous priority, with margin discipline: Management is evaluated on top line, market share, and bottom line; the global group is aligned on growth and penetration for India, but spending is described as smart and focused.
• What to watch next quarter: The pace of HCP reach doubling, any concrete innovation launches, and whether the OTC policy materializes to unlock direct consumer communication.

Post-Demerger Rebuild & Recall Recovery

• Demerger completed, entity now independent: Sanofi Consumer Healthcare India Ltd listed after demerger; this was the first investor meet post-listing, and the company now has full ownership of its P&L and supply chain at the country level.
• Organization rebuilt from scratch: The company hired what management calls the best talent from the FMCH world, built a KPI-driven performance culture, more than doubled women employees, and earned recognition as a preferred workplace and B-Corp certification.
• Recalls were precautionary, all products back: Recalls were done in abundant caution to maintain quality; all four recalled products are now back in the market and moving quickly toward leadership positions. Two have already reached their pre-recall run rate.
• HCP feedback validates brand superiority: Doctors told the company they were delighted by the return because patients did not get a great experience from alternative brands used during the absence, further establishing the company's superiority in their mind.

Bakshi: "on a couple of them, honestly, and that's the feedback coming from HCPs, they were delighted that we had come back because they did not get a great experience from other brands that they had used."

Brand Portfolio & Category Strategy

• Core brands carry deep equity: Combiflam stayed among the top five brands despite no HCP engagement for 15 years, a fact management cites as proof of brand strength. All four core brands are now actively promoted to HCPs.
• Category headroom is substantial: Allergy affects 3 in 10 people, pain episodes touch 9 in 10, and 7 in 10 Indians are Vitamin D deficient; all categories are growing with significant penetration upside.
• Category leadership brings expansion responsibility: The company is number one or number two in most categories it operates in, so management sees category expansion as its role. Core brands still have significant headroom in market share and penetration.
• Innovation pipeline is active but unquantified: Allegra D launched last year as a unique congestion formulation; management says meaningful innovations are coming very soon, but declined to quantify R&D investment or output expectations.
• New categories under evaluation: The company continues to evaluate entry into other consumer health categories beyond current pillars, but no decision has been made on which category or when.

Bakshi: "With the virtue of the fact that we are either number one or number two in most categories that we play in, I think the role of category expansion also lies with us."

Channel & Reach Expansion

• HCP reach is the top priority: The plan is to double face-to-face doctor reach in 2026 itself, with digital reach adding to the 50,000 HCP base. On certain specialties, there is a clear gap today.
• Sales force stands at roughly 350 reps: Each rep now carries a "one touch" app providing real-time data on achievements and targets, enabling faster decision-making. AI is used to generate better detailing content versus competitors.
• Retail pharmacy investment is new: For the first time in years, the company started investing in retail pharmacies for visibility and pharmacist education, areas where direct store coverage was not at the desired level.
• Regional footprint is North-heavy: The business is over-indexed in the North, including UP, which is a historical stronghold. East is where the company wants to make more inroads; West and South are as per category.
• Reach models still being evaluated: Management is looking at both increasing productivity from the current sales force and using third-party models to reach more HCPs cost-effectively, with a clear roadmap for the former and ongoing evaluation of the latter.

Consumer Engagement & OTC Unlock

• Direct consumer communication started for the first time: Initiatives include educating consumers on common cold versus allergy, social media campaigns for DePURA and Allegra, and a Combiflam activation at Mumbai's Ganesh festival.
• Consumer behavior is shifting: 5.3 crore people access health information online, 1 in 4 self-medicate, and 15% ask a pharmacist; social media is the largest influencer in the VMS category.
• OTC regulation is the big unlock, timing uncertain: Management expects the OTC policy to come out very soon, and sees direct consumer communication as the biggest growth lever because it removes current constraints on building categories. The timeline remains conditional.
• Brand extensions target direct-to-consumer spaces: Combiflam cream, part of the portfolio where the company can talk to consumers directly, was used at the Lalbaugcha Raja event as the first opportunity for direct consumer communication.

Bakshi: "I think the biggest unlock will be direct consumer communication, you know, the moment OTC comes in, and then that gives us the freedom to really, again, build the category from where we want to today, which is today a constraint as we speak."

Digital, AI & Operating Model

• AI investment has begun across functions: The company started investing in AI to improve productivity; most creatives going forward will be AI-enabled, and a dedicated in-house AI creative team has been established.
• India is an empowered, India First geography: Management describes the country business as very empowered, with complete P&L ownership, almost 100% local production, and many initiatives designated India First by the global group.
• Supply chain now fully independent: The company is now fully independent as an entity for supply chain operations; the CMO network is very well covered with no production or supply issues foreseen.
• Culture built around challenger mindset: The organization promotes a culture of challenging the status quo, supported by a differentiated reward structure.

Bakshi: "I can tell you very clearly, it is a very empowered country business. I have had presentations, you know, to all the global teams and India is a key geography for investment. A lot of initiatives are India First now."

Margins, Investment & Capital Allocation

• A&P spend has stepped up materially: A&P moved from very low single digits to mid-teens as a percentage of revenue, funding brand building, HCP engagement, and consumer communication for the first time.
• Growth is the clear priority, with margin discipline: Management states sustainable, profitable growth is the agenda; spending is described as smart and focused, not a blank check. The MD is tracked on bottom line as one of three KPIs alongside top line and market share.
• Inorganic opportunities are under discussion, no action yet: The company keeps discussing with the group what to look at from an inorganic perspective, weighing make versus buy given known multiples in India and the country's manufacturing ecosystem. Global is open to discussions but questions remain unanswered.
• Unlisted products stay with the parent for now: Discussions continue about bringing other products into the listed entity, but the current decision is to continue with the existing arrangement.

Bakshi: "I think if you ask me one answer to this, it's very clearly growth and penetration that we want to achieve in India. And that's where the global group is completely aligned."

Guidance & Commitments

Key Metrics